Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia

Muzaffar H. Qazilbash; Zhenhong Qu; Chifra Hosing; Daniel Couriel; Michele Donato; Sergio Giralt; Richard Champlin

doi:10.1002/ajh.20413

Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia

Muzaffar H. Qazilbash, Zhenhong Qu, Chifra Hosing, Daniel Couriel, Michele Donato, Sergio Giralt, Richard Champlin

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Autoimmune hemolytic anemia (AIHA) is a well-recognized complication of allogeneic bone marrow transplantation (BMT) and can affect up to 5% patients. Several recent case reports suggested the efficacy of anti-CD20 monoclonal antibody, rituximab, in treating this condition. We report our experience with a 21-year-old female with accelerated-phase chronic myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation from a matched, unrelated donor. The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity.

Original language	English (US)
Pages (from-to)	43-45
Number of pages	3
Journal	American journal of hematology
Volume	80
Issue number	1
DOIs	https://doi.org/10.1002/ajh.20413
State	Published - Sep 2005

Keywords

Acute liver failure
Autoimmune hemolytic anemia
Rituximab

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.20413

Cite this

@article{ccf86aa8b9bd43e48eb50ecf5c8a7225,

title = "Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia",

abstract = "Autoimmune hemolytic anemia (AIHA) is a well-recognized complication of allogeneic bone marrow transplantation (BMT) and can affect up to 5% patients. Several recent case reports suggested the efficacy of anti-CD20 monoclonal antibody, rituximab, in treating this condition. We report our experience with a 21-year-old female with accelerated-phase chronic myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation from a matched, unrelated donor. The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity.",

keywords = "Acute liver failure, Autoimmune hemolytic anemia, Rituximab",

author = "Qazilbash, {Muzaffar H.} and Zhenhong Qu and Chifra Hosing and Daniel Couriel and Michele Donato and Sergio Giralt and Richard Champlin",

year = "2005",

month = sep,

doi = "10.1002/ajh.20413",

language = "English (US)",

volume = "80",

pages = "43--45",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia

AU - Qazilbash, Muzaffar H.

AU - Qu, Zhenhong

AU - Hosing, Chifra

AU - Couriel, Daniel

AU - Donato, Michele

AU - Giralt, Sergio

AU - Champlin, Richard

PY - 2005/9

Y1 - 2005/9

N2 - Autoimmune hemolytic anemia (AIHA) is a well-recognized complication of allogeneic bone marrow transplantation (BMT) and can affect up to 5% patients. Several recent case reports suggested the efficacy of anti-CD20 monoclonal antibody, rituximab, in treating this condition. We report our experience with a 21-year-old female with accelerated-phase chronic myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation from a matched, unrelated donor. The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity.

AB - Autoimmune hemolytic anemia (AIHA) is a well-recognized complication of allogeneic bone marrow transplantation (BMT) and can affect up to 5% patients. Several recent case reports suggested the efficacy of anti-CD20 monoclonal antibody, rituximab, in treating this condition. We report our experience with a 21-year-old female with accelerated-phase chronic myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation from a matched, unrelated donor. The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity.

KW - Acute liver failure

KW - Autoimmune hemolytic anemia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=24344448573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344448573&partnerID=8YFLogxK

U2 - 10.1002/ajh.20413

DO - 10.1002/ajh.20413

M3 - Article

C2 - 16138357

AN - SCOPUS:24344448573

SN - 0361-8609

VL - 80

SP - 43

EP - 45

JO - American journal of hematology

JF - American journal of hematology

IS - 1

ER -

Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this